H Pylori Infection Clinical Trial
Official title:
Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy
- Detection of primary antimicrobial susceptibility and resistance of Helicobacter Pylori infection. - Detection of resistance and virulence genes of Helicobacter Pylori infection. - Assessment of H pylori carcinogenicity gene. - Evaluation of outcome and efficacy of antibiotics regimen will be used in our research. - Evaluation of effect of other factors as diet (fatty and spicy meal), drugs as NSAIDs use, antibiotics for any cause on response of H pylori to antibiotics regimen.
Helicobacter pylori (H. pylori) infection is one of the most common infections in humans, affecting more than half of the world population. New infections are thought to occur as a consequence of direct human-to-human transmission or environmental contamination. The prevalence of the infection varies widely in rural developing areas (more than 80%) compared to urban developed ones (less than 40%), as a consequence of different socioeconomic and hygienic conditions . The vertical mode is infection spread from ascendant to descendent within the same family, while horizontal transmission involves contact with individuals outside the family or environmental contamination. Most individuals are infected by Helicobacter pylori during early childhood; in developing countries. Successful eradication is important to prevent the development of antibiotic resistance, as well as to reduce the number of treatments and procedures. Thus, national/ regional antibiotic resistance data could be used to guide treatment regimens for H pylori infection . Several clinical factors associated with increased rates of antibiotic resistant H. pylori, including history of previous antibiotic exposure, increasing age, female gender, ethnicity/race, extent of alcohol use, and non-ulcer dyspepsia . The primary antibiotic resistance of H. pylori is increasing worldwide. The overall resistance rate was found to be 4.55% for amoxicillin; 27.22% for clarithromycin; 39.66% for metronidazole; and 22.48% for levofloxacin. Therefore, drug susceptibility result of these antibiotics is necessary to select the appropriate drug for the successful eradication of the infection. Helicobacter pylori exhibit specific geographic distributions that are related to clinical outcomes. Despite the high infection rate of H. pylori throughout the world, the genetic epidemiology surveillance of H. pylori still needs to be improved. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03629587 -
Helicobacter Pylori and it's Hematological Impact
|
||
Recruiting |
NCT03347513 -
Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?
|
Phase 4 | |
Completed |
NCT05680532 -
The Improvement of Black Raspberry in Obese and Mild AZ Patients Infected With H. Pylori
|
N/A | |
Recruiting |
NCT06275204 -
H. Pylori Screen-and-treat Study in a Population of Young Adults
|
||
Completed |
NCT03857425 -
Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets
|
Phase 4 | |
Recruiting |
NCT03555526 -
Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection
|
Phase 4 | |
Not yet recruiting |
NCT05789550 -
HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
|
||
Not yet recruiting |
NCT03911791 -
Screening of Helicobacter Pylori in Children of Positive Infected Mothers
|